Literature DB >> 105628

In-vitro methods for determining minimal lethal concentrations of antimicrobial agents.

A L Barry, R A Lasner.   

Abstract

To determine the minimal lethal concentration of an antimicrobial agent, broth dilution tests may be performed and then a sample from each tube showing no visible growth may be subcultured onto a drug-free agar medium. By counting the number of viable cells recovered from each tube, the minimal concentration of drug required to kill 99.9% of the cells in the initial inoculum can be determined. Studies were undertaken to determine the circumstances under which false-negative tests could occur as a result of continued inhibition of growth by the antimicrobic carried over in the sample. Drug carryover did significantly reduce the number of viable cells recovered from broth containing relatively high concentrations of antimicrobic: the larger the sample, the greater the effect of drug carryover. The effect was minimal with samples of 10 microliter or less. Furthermore, the effect of drug carryover was reduced by spreading the sample over the surface of an agar medium. The relative precisions of four methods for performing subcultures with such small-volume samples were determined; coefficients of variation were 16-25%. Sampling errors inherent in the procedure for subculturing broth tubes should be taken into consideration when interpreting results of individual tests, and replicate subcultures will improve the reliability of the colony counts.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 105628     DOI: 10.1093/ajcp/71.1.88

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  17 in total

1.  Evaluation of two methods for overcoming the antibiotic carry-over effect.

Authors:  R H Eng; S M Smith; C E Cherubin; E N Tan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-01       Impact factor: 3.267

2.  Influence of technical factor variations on serum inhibition and bactericidal titers.

Authors:  B F Woolfrey; R T Lally; K R Tait
Journal:  J Clin Microbiol       Date:  1986-06       Impact factor: 5.948

3.  Discrepancies between MBC and actual killing of viridans group streptococci by cell-wall-active antibiotics.

Authors:  P R Meylan; P Francioli; M P Glauser
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

4.  Antistaphylococcal activity of ceforanide and cefonicid in the presence of human serum.

Authors:  A L Barry; R N Jones; R R Packer
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

Review 5.  Problems in in vitro determination of antibiotic tolerance in clinical isolates.

Authors:  J C Sherris
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

6.  MBCs for Staphylococcus aureus as determined by macrodilution and microdilution techniques.

Authors:  C J Shanholtzer; L R Peterson; M L Mohn; J A Moody; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

7.  Lack of in vivo and in vitro bactericidal activity of N-formimidoyl thienamycin against enterococci.

Authors:  R Auckenthaler; W R Wilson; A J Wright; J A Washington; D T Durack; J E Geraci
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

8.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

9.  Effect of antibiotics on toxin production and viability of Clostridium perfringens.

Authors:  D L Stevens; K A Maier; J E Mitten
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

10.  Comparison of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens.

Authors:  D L Stevens; B M Laine; J E Mitten
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.